NCT06940180 - Toripalimab With Chemotherapy for Sinus Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 17, 2025

Primary Completion Date

February 1, 2028

Study Completion Date

February 1, 2029

Conditions

Sinonasal CancerParanasal Sinus NeoplasmsSquamous Cell CarcinomaSinonasal Undifferentiated CarcinomaLocally Advanced Head and Neck Cancer

Interventions

DRUG

Toripalimab

An anti-PD-1 monoclonal antibody, single-use vial, via intravenous (into the vein) infusion per protocol.

DRUG

Carboplatin

An antineoplastic agent, multi-dose vials, via intravenous (into the vein) infusion per standard of care.

DRUG

Docetaxel

A taxoid antineoplastic agent, single-dose vials, via intravenous (into the vein) infusion per standard of care.

RADIATION

Radiation Therapy

per standard of care

DRUG

Cisplatin

An antineoplastic agent, single-dose vials, via intravenous (into the vein) infusion per standard of care.

Trial Locations (2)

RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston